Sensipar^® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Sensipar^® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Sensipar^® is indicated for the treatment of severe hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy.

Important Safety Information

• Sensipar^® treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges.
• Before starting Sensipar^®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar^® therapy.
• Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar^®.
• While on Sensipar^®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
• Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar^®.
• Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
• In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea. If you have any questions about this information, be sure to discuss them with your doctor.

Additional Safety Information for Patients with Primary HPT

• While on Sensipar^®, your doctor should perform regular blood tests to monitor calcium levels.
• In clinical trials, the most common side effects reported in patients were nausea, vomiting, and tingling/numbness of the skin.